Announcements
The International Progressive MS Alliance is bringing researchers and other stakeholders from around the world together to solve four challenging research problems. Our single aim is to understand and overcome some of the biggest barriers to treatment development for progressive MS.
Visit this section regularly to find out about the latest research, developments, news and announcements from the Alliance and its members. We will occasionally feature stories from other sources where they have a direct impact on our work and our goal.
- Rehabilitation and symptom management at the Alliance’s 3rd Scientific Congress
- Alliance Collaborative Network Award identifies links between diet, gut bacteria and immune activity in a mouse model
- 100 Years of Mateship: ‘An amazing journey of perseverance’
- Coming together in Amsterdam: the MSIF movement
- Results Published from Trial of Siponimod in Secondary Progressive MS
- Results Announced from Clinical Trial of Idebenone in Primary Progressive MS
- European Medicines Agency approves first disease-modifying therapy for primary progressive MS
- Negative results from phase 2 clinical trial for laquinimod in primary progressive MS
- First disease modifying therapy for primary progressive MS in Europe
- Interesting results of phase 2 clinical trial for people with progressive MS
- Live webinar – Drs. Arnold, Martino and Quintana discuss their Alliance projects
- Two Alliance members fund multi-million pound trial to investigate if statins could become MS treatment
- Report from the third annual Industry Forum meeting
- First disease modifying therapy for primary progressive MS
- FDA extends review of ocrelizumab
- Live webcast with Dr. Francisco Quintana
- €12.6 million awarded to 3 projects in global effort to end progressive MS
- Positive phase III results showing efficacy of BAF312 (siponimod) in patients with secondary progressive MS
- Progressive MS Alliance Industry Forum: maximizing collective impact to enable drug development
- Federal Drug Administration grants priority review for ocrelizumab in primary progressive and relapsing MS
- Update on Challenge and Infrastructure Awards
- Alliance stakeholders consider challenges and next steps at the second scientific congress
- Lay members join the Scientific Steering Committee
- Federal Drug Administration designates experimental therapy, ocrelizumab as ‘Breakthrough Therapy’ for treatment of primary-progressive MS
- Epilepsy drug could protect nerves from damage in MS
- Scientific meeting in Boston – March 2015
- Alliance expands worldwide
- Progressive MS Alliance boosts research
Sign up to our e-newsletterfor updates from our growing global initiative to end progressive MS
Clicking submit confirms that you consent to MSIF sending you the Progressive MS Alliance newsletter
Please note, you must be aged 18 or older to subscribe to our newsletters.
Click here to read our Terms & Conditions and Privacy Policy